DocGo Inc.
HealthcareNASDAQ:DCGO · NASDAQ Capital Market
+$0.01 today
Vol 0.35M · Avg 0.99M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-126.7%
avg -21.5%
ROIC
-55.8%
avg -10.9%
ROA
-84.0%
avg -13.7%
Analysis
ROIC is currently the strongest return metric at -55.8% versus its period average of -10.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lee Bienstock | Chief Executive Officer & Director | $1.65M | — | 41 | $2.80M | 2.84% |
Ely D. Tendler | General Counsel, Secretary & Director | $1.23M | — | 58 | $258,795.00 | 0.26% |
Norman Rosenberg | Treasurer & Chief Financial Officer | $953,743.00 | — | 56 | $1.22M | 1.24% |
Stephen Sugrue | Chief Compliance Officer | $623,251.00 | — | 53 | $636,602.00 | 0.64% |
James Powell | Chief Executive Officer of Clinical Practice Group & Member of Medical Advisory Board | — | — | — | $240,999.00 | 0.24% |
Eiwe Lingefors | Chief Information Officer | — | — | — | — | — |
Mike Cole | Vice President of Investor Relations | — | — | — | — | — |
Rosemarie Milano | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$15,333.50
Net Sentiment
$15,333.50
Net selling
Most Active
Tendler Ely D
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $15,333.50 over the last 12 months. That adds up to net selling of $15,333.50. Tendler Ely D was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +87.9% | -14.9% (4yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +87.9% over three years. Forward estimates point to Revenue at -14.9% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Quipt Home Medical Corp.
QIPT
$162.30M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Microbot Medical Inc.
NASDAQ:MBOT
$81.12M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
InspireMD, Inc.
NSPR
$34.19M
Who manages DCGO?
DocGo Inc. (DCGO) lists 8 active executives. The top listed executive is Norman Rosenberg, Treasurer & Chief Financial Officer.
Are DCGO insiders buying or selling?
Recent insider activity shows net buying of $37.98M.
Explore More
Continue the stock analysis
Jump to another research area for this company.